Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) --  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies, today announced the appointment of Jennifer Fox as its Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., Ph. D as Head of Research and Development and Chief Medical Officer.

“We are thrilled to welcome Tanya and Jen to our executive team,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “Tanya is a deeply experienced physician-scientist leader and Jen is a seasoned healthcare finance and corporate development leader. With their decades of industry leadership experience, they will each be an invaluable addition to Zenas as we head into our next phase of growth, advancing multiple global programs in late-stage clinical development with a goal to deliver differentiated I&I directed therapies to patients in need around the world.”

Ms. Fox is an experienced finance and corporate development executive with an extensive track record in corporate finance and healthcare investment banking, advising numerous private and public companies with respect to strategy, financings and mergers and acquisitions. Prior to joining Zenas, Ms. Fox served as Chief Financial Officer at Nuvation Bio, a publicly traded biotechnology company. She previously served as a Managing Director and Co-Head of North America Healthcare Corporate and Investment Banking Group at CitiGroup. Prior to CitiGroup, Ms. Fox held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America and Prudential Securities. She holds B.S. degrees in finance and marketing from Manhattan College.

Dr. Fischer is a physician-scientist with deep experience in academia and at both pharmaceutical and biotechnology companies, leading early and late-stage research and development programs across multiple therapeutic areas, including neurology and rare diseases. Prior to joining Zenas, she served as Chief Development Officer and Head of Translational Medicine at Biohaven, a publicly traded biopharmaceutical company. Dr. Fischer began her industry career at Bristol Myers Squibb and held R&D leadership roles of increasing responsibility at EMD-Serono, Sanofi-Genzyme and Alnylam. She is a neurologist and held appointments at Yale University School of Medicine following the completion of her Neurology residency at Yale New Haven Hospital. She obtained MD and PhD degrees from the University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School and Rutgers University, respectively, and was awarded the prestigious Presidential Early Career Award for Scientists and Engineers (PECASE).

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies, including in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc. Obexelimab is currently being studied in a global Phase 3 clinical study in patients with IgG4 Related Disease and a global Phase2/3 study in patients with warm autoimmune hemolytic anemia (wAIHA). Clinical development of obexelimab for Multiple Sclerosis and Systemic Lupus Erythematosus is under evaluation.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 3 (SApHiAre) study for the treatment of wAIHA is available at clinicaltrials.gov: NCT05786573.


Investor and Media Contact: Joe Farmer, President & COO Zenas BioPharma IR@zenasbio.com  


Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

THỦ THUẬT HAY

Thủ thuật di chuyển nhiều ứng dụng cùng lúc trên Galaxy S8

Trên Samsung Galaxy S8 và S8 Plus có tính năng cho phép người dùng có thể di chuyển nhiều biểu tượng, icon ứng dụng cùng một lúc trên màn hình, hoặc khay ứng dụng.

Cách sửa lỗi 100% Disk trên Windows

Bạn đang sử dụng Windows 8.1/10 và thường xuyên rơi vào tình trạng 100% Disk Usage và CPU? Hôm nay, TCN sẽ tổng hợp các cách có thể giúp bạn xử lý lỗi 100% Disk trên Windows.

Cách gỡ bỏ nhiều ứng dụng cùng lúc dành cho thiết bị Android đã root và chưa root

Đối với những thiết bị chưa root bạn có thể gỡ bỏ cùng lúc nhiều ứng dụng với tiện ích hỗ trợ Easy Uninstaller, cách sử dụng khá đơn giản và hầu như ai cũng làm được.

Kích hoạt nhanh phiên bản KMSPico Office 2016

KMSPico Office 2016 Activator (Word, Excel, PowerPoint) là một công cụ tuyệt vời được sử dụng để kích hoạt các sản phẩm của Microsoft. Nó là một công cụ tuyệt đối không có virus và đáng tin cậy đối với nhiều người.

Hướng dẫn tải và sử dụng Minecraft Launcher trên máy tính

Minecraft, một tựa game đình đám với lối chơi thế giới mở rộng lớn với các chế độ chơi như: sinh tồn, sáng tạo, phiêu lưu... với những khối vuông đa dạng, bạn có thể xây dựng riêng cho mình những công trình với sức

ĐÁNH GIÁ NHANH

Đánh giá Asus A556U: Hiệu năng ổn định, màn hình lớn và âm thanh chất lượng

Là sản phẩm đại diện cho serie A mới ra mắt của Asus, A556 có những tính năng và hiệu năng như thế nào. Hãy cũng FPTShop tìm hiểu qua bài đánh giá hôm nay

Thả rơi Samsung Galaxy Z Fold3 5G và cái kết không thể ngờ tới

PhoneBuff, một kênh Youtube vừa thử nghiệm độ bền Fold3 5G bằng cách thả rơi. Kết quả sau các màn thả rơi Samsung Galaxy Z Fold3 5G khiến nhiều người phải bất ngờ. Bị “trọng thương” nhưng máy vẫn hoạt động bình thường.

Đánh giá nhanh smartphone tầm trung Nokia 7 Plus

Nokia 7 Plus có thiết kế kim loại nguyên khối với hợp kim nhôm đạt chuẩn 6000, kiểu dáng bên ngoài khá đẹp với độ hoàn thiện cao cho cảm giác cầm nắm thoải mái. Máy có kích thước lần lượt 158.4 x 75.6 x 8mm, trọng